Effects of Nateglinide on Fasting Free Fatty Acid in Type 2 Diabetic Patients
Fu-neng WANG,Zhi-hong LIAO,Guo-liang HU,Yan-bing LI,Xiang-zhong OU,Jian-ping WENG
DOI: https://doi.org/10.3321/j.issn:1672-3554.2006.01.022
2006-01-01
Abstract:[Objective] To investigate the effects of nateglinide on fasting free fatty acids(FFA)in newly diagnosed type 2 diabetic patients.[Methods] The study was a 12-week double-blind,randomized,parallel controlled trial.Forty-two patients with newly diagnosed type 2 diabetes(fasting plasma glucose(FPG)7 mmol/L～13.3 mmol/L,or FPG6 mmol/L ~6.9 mmol/L and 2-h postload glucose(2hPG)≥11.1 mmol/L)without previous treatment of hypoglycaemic or antihyperlipidemic agents were randomized to receive monotherapy with repaglinide(n =21)(0.5 mg/meal,maximum dose 1 mg/meal)or nateglinide(n =21)(60 mg/meal,maximum dose 90 mg/meal)for 12 weeks.Before treatment,serum lipid profiles,FPG,glycohemoglobin(HbA1c),fasting FFA,2hPG were measured,and in the next morning,intravenous glucose insulin releasing test(IVG-IRT)was performed,insulin levels 0 min,and 2 min,4 min,6 min,10 min after intravenous injection of 50 ml 50% GS were measured.After 12 weeks follow up,the above measurement and IVG-IRT were repeated 24 h after medication cessation.[Results]Thirty-seven patients had completed the trial,19 in repaglinide and 18 in nateglinide.There were no statistical differences in gender,age,duration and baseline body mass index(BMI),FPG,2hPG,HbA1c,TC,TG,HDL-C,LDL-C,FFA,FINS,HOMA-B(homeostatic model assessment of B-cell function),HOMA-IRI(homeostatic model assessment insulin resistant index),and AIR(acute insulin respond,incremental insulin area over the basal level from 0 to 10 min was calculated and defined as AIR)between the repaglinide group and the nateglinide group(P0.05).After treatment,FFA in nateglinide group had significantly reduced,from 0.47 mmol/L±0.18 mmol/L to 0.36 mmol/L±0.16 mmol/L(P 0.05).while there were no change for FFA in repaglinide group.No statistical differences in BMI,TC,TG,HDL-C,LDL-C,FINS averages of 37 patients between baseline and after treatment could be seen But FPG,2hPG,HbA1c,and HOMA-IRI had significantly reduced in both groups.At the same time,there were significant increase in HOMA-B and AIR(P 0.05),but no statistical differences were seen between the groups(P 0.05).[Conclusion] Nateglinide can significantly lower fasting FFA level in type 2 diabetic patients,and this action may be independent to the improvement of insulin secretion.